Report cover image

Spinal Cord Injury (SCI)

Publisher Reach Market Research
Published Jun 01, 2021
Length 24 Pages
SKU # RMR19136514

Description

MarketVue®: Spinal Cord Injury (SCI)

The MarketVue®: Spinal Cord Injury (SCI) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Spinal Cord Injury (SCI) report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Kringle Pharma
• Eusol Biotech
• Acorda Therapeutics
• AbbVie
• Pharmazz
• Mitsubishi Tanabe Pharma
• ReNetX Bio
• Histocell
• Linage Cell Therapeutics
• AlaMab Therapeutics
• K Stem Cell (Biostar Stem Cell Research Institute)
• InVivo Therapeutics

Key drugs mentioned:
• Methylprednisolone
• KP-100IT
• ES 135
• Fampridine-SR
• Sovateltide / PMZ-1620 (Tycamzzi)
• Elezanumab
• MT-3921
• AXER-204
• HC016 Neurosave (FAB117-HC)
• OPC1
• ALMB-0166
• AstroStem
• Neuro-Spinal Scaffold

Please note: the online download version of this report is for a global site license.

Table of Contents

24 Pages
1. DISEASE OVERVIEW
A neurologic condition of loss of function and feeling
Overview
Table 1.1. American Spinal Cord Injury Association (ASIA) impairment scale
Acute and chronic spinal cord injury
Figure 1.2. symptoms of spinal cord injury
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. Prevalent cases of spinal cord injury by region, 2020
Table 2.1 Prevalence of spinal cord injury by country, US and EU5, 2020
Figure 2.2. Fast facts on spinal cord injury patient population.
3. CURRENT TREATMENT
Treatment goals
Figure 3.1. Primary goals of treating spinal cord injury
Standard of care
Figure 3.2. Percentage of patients who undergo surgery
Diagnosis and treatment flow
Figure 3.3. Diagnosis and treatment flow for spinal cord injury
Drug-treatment rates
Figure 3.4. Treating physicians and their patient load
Is there a role for therapeutic hypothermia in SCI
Figure 3.5. Percentage of acute SCI patients receiving therapeutic hypothermia
Treating physicians and their patient load
Figure 3.6. Professionals involved in spinal cord injury patient care
Figure 3.7. Neurologist SCI patient load
Must-know treatment dynamics
Evolution of treatment
Figure 3.8. Potential timeline of spinal cord injury market development
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in spinal cord injury
Figure 4.2. Physician rankings of unmet needs in spinal cord injury
Additional neurosurgeon commentary on unmet needs.
Barriers to care
Figure 4.3 Percent of neurologists ranking barrier as “impactful” to optimal spinal cord injury care.
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Percentage of neurologists who rated emerging target or approach as “promising”
Figure 5.2. Percentage of neurologists ranking product attribute among top three most important
Figure 5.3. Number of emerging therapies addressing unmet needs in SCI
Table 5.1. Emerging clinical-stage therapies for SCI
Figure 5.4. Neurologists’ awareness of emerging spinal cord injury therapies
6. VALUE & ACCESS
Overview
Figure 6.1. Payer mix for spinal cord injury
Healthcare costs and living expenses of SCI patients
Figure 6.2. Yearly expenses (health care costs and living expenses)
Table 6.1. Yearly expenses (health care costs and living expenses)
Table 6.2. Categories of healthcare costs for SCI and areas of potential impact of new therapies
7. METHODOLOGY
Primary market research methodology
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us